PKA-IN-2
PKA-IN-2 (Compound j1) is a serine/threonine kinase J-PKAcα-targeting inhibitor with an IC50 of 6.3 nM. PKA-IN-2 can be used for liver cancer like fibrolamellar hepatocellular carcinoma research.
For research use only. We do not sell to patients.
- Formula: C15H13N5S
- Molecular Weight:295.36
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
IC50 & Target
[1]|
J-PKACα 6.3 nM (IC50) |
Chemical Information
-
Molecular Weight 295.36
-
Formula C15H13N5S
-
SMILES
N1(C2=NC=NC=C2)CCSC(C3=C4C(NC=C4)=NC=C3)=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Liver Cancer Modeling
Liver cancer can be classified into primary liver cancer and secondary liver cancer. Secondary liver cancer is the metastatic liver cancer. Primary liver cancer includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and fibrolamellar HCC, of which HCC is the most common form, accounting for approximately 90% of primary liver cancers[1]. HCC mouse models include chemical agent-induced models, transplanted tumor models, and genetic engineered models.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
PKA-IN-2 Related Classifications
HY-176532 Related Classifications
Powered by Bioz